DMDonna Milne

Donna Milne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Donna Milne has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Co-design and development of online video resources about immunotherapy with patients and their family

    by Amelia Hyatt, Bryce Morkunas, Diane Davey, Alesha A. Thai, Megan Trewhella, Mary Duffy, Tamara Dawson, Peter Gourlay, Justin Hutchison, Donna Milne


  • Open Access

    Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

    by Fiona A Lynch, Lynda Katona, Michael Jefford, Allan Ben Smith, Joanne Shaw, Haryana M Dhillon, Steve Ellen, Jo Phipps-Nelson, Julia Lai-Kwon, Donna Milne, et al.

    Immunotherapies and targeted therapies have revolutionised treatment of metastatic melanoma and improved survival rates. However, survivors treated with novel therapies are vulnerable to high levels of fear of cancer recurrence or progression (FCR). Existing FCR interventions have rarely been trialled in people with advanced cancer. The current study aimed to evaluate the acceptability and feasibility of Fear-Less: a stepped-care model to treat FCR in people with metastatic melanoma treated with immunotherapy or targeted therapy. Sixty-one outpatients with metastatic melanoma were screened using the Fear of Cancer Recurrence Inventory Short Form (FCRI-SF) and Fear of Progression Questionnaire Short Form (FoP-Q-SF). Survivors with subthreshold FCR were stratified to a self-management intervention while those with clinical levels of FCR were provided with an individual therapy, Conquer Fear. Survivor experience surveys and rescreening were administered post-intervention completion. Results indicated that Fear-Less was an acceptable and feasible FCR intervention. Results provided preliminary support for the potential impact of Fear-Less in reducing FCR. Fear-Less is a promising first step in providing an acceptable and feasible stepped-care model to treat FCR in survivors with metastatic disease.


  • Open Access

    i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol

    by Amelia Hyatt, Karla Gough, Andrew Murnane, George Au-Yeung, Tamara Dawson, Elizabeth Pearson, Haryana Dhillon, Shahneen Sandhu, Narelle Williams, Elizabeth Paton, et al.

    Introduction There is increasing evidence demonstrating the benefits of exercise in counteracting cancer treatment-related fatigue. Immunotherapy is an established treatment for advanced melanoma, and is associated with fatigue in a third of patients. The safety and efficacy of exercise in counteracting treatment-related fatigue in patients with advanced melanoma receiving immunotherapy are yet to be determined. This study aims to assess the safety, adherence to and acceptability of a mixed-methods parallel-group, pilot randomised controlled trial of a personalised, 12-week semi-supervised exercise programme prescribed by an exercise physiologist (iMove) in 30 patients with stage IV melanoma scheduled to commence immunotherapy: single agent ipilimumab, nivolumab or pembrolizumab, or combination ipilimumab and nivolumab. The trial will be used to provide preliminary evidence of the potential efficacy of exercise for managing fatigue. Methods and analysis Thirty participants will be recruited from a specialist cancer centre between May and September, 2019. Participants will be randomised 1:1 to receive iMove, or usual care (an information booklet about exercise for people with cancer). Feasibility data comprise: eligibility; recruitment and retention rates; adherence to and acceptability of exercise consultations, personalised exercise programme and study measures; and exercise-related adverse events. Patient-reported outcome measures assess potential impact of the exercise intervention on: fatigue, role functioning, symptoms and quality of life. Follow-up will comprise five time points over 24 weeks. Physical assessments measure physical fitness and functioning. Ethics and dissemination This study was reviewed and approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee (HREC/48927/PMCC-2019). The findings from this trial will be disseminated via conference presentations and publications in peer-reviewed journals, and by engagement with clinicians, media, government and consumers. In particular, we will promote the outcomes of this work among the oncology community should this pilot indicate benefit for patients. Trial registration number ACTRN12619000952145; Pre-results.


  • Open Access

    Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?

    by Annie Wong, Alex Billett, Donna Milne

    Background: Immunotherapy has resulted in unprecedented improvements in survival and maintained quality of life for many patients with advanced melanoma. However, durable responses are observed in only a minority of patients, and severe treatment side effects are experienced by 5%–30%. There are no reliable tests that can differentiate between patients who are likely to respond to immunotherapy and those who will not. Hence, new challenges have arisen as clinicians try to facilitate patients in their decision-making regarding immunotherapy. Furthermore, little is known about the real-world patients’ experience and understanding of immunotherapy outside the clinical trial setting. Here, we explore the perspectives of patients undergoing immunotherapy for melanoma and focus on factors that influenced their treatment decision-making. Materials and Methods: Twenty-three in-depth semistructured interviews were conducted with patients receiving pembrolizumab for stage IV melanoma at an Australian public cancer hospital. Patients were recruited at a range of time points after commencing therapy, and their experience of treatment was explored. Interviews were audio recorded, transcribed verbatim, coded, and analyzed thematically. Results: Immunotherapy is viewed as a symbol of hope, with high-profile anecdotes reinforcing this perception. Only a minority of patients expressed a good understanding of the likely efficacy and potential treatment side effects. Patients are reliant on their clinicians’ recommendation regarding immunotherapy treatment decisions. Conclusion: Novel treatments such as immunotherapy provide significant hope for patients. This may influence their preference for immunotherapy over and above the usual considerations of the trade-off between efficacy and toxicity. Careful counsel and individualized patient resources may further facilitate treatment decision-making. Implications for Practice: This study highlighted some of the misconceptions held by patients that need to be addressed when discussing the possibility of receiving treatment with immunotherapy for advanced melanoma. Patients placed a lot of importance on high-profile anecdotes rather than truly understanding likely outcomes of treatment based on personal circumstances. The majority of patients had a poor understanding of the potential side effects and long-term implications of treatment with immunotherapy. Careful counsel is required in order to facilitate informed decision-making about treatment and to ensure possible side effects are known and appreciated. Further research is needed to develop tools to aid decision-making in everyday clinical practice.


  • Open Access

    Exercise Behaviors and Fatigue in Patients Receiving Immunotherapy for Advanced Melanoma: A Cross-Sectional Survey via Social Media

    by Amelia Hyatt, Allison Drosdowsky, Narelle Williams, Elizabeth Paton, Fiona Bennett, Hayley Andersen, Jared Mathai, Donna Milne

    Objective: Treatment with immunotherapy has positively changed the long-term outlook of many patients with advanced melanoma; however, fatigue is a common and debilitating side effect. Evidence indicates exercise can improve treatment-related fatigue for patients receiving chemotherapy and radiotherapy. However, currently little is known about exercise behaviors and preferences of patients receiving immunotherapy. This project aimed to describe self-reported levels of fatigue related to immunotherapy; patient perspectives of exercise behaviors; and barriers and facilitators to engagement in exercise for patients receiving, or recently completed immunotherapy for unresectable stage III and stage IV melanoma. Method: A cross-sectional purpose-built survey was distributed to members of the Melanoma Patients Australia closed Facebook group via an online survey platform. The survey remained active for 1 month, with 3 posts during this time inviting members to participate. Results: A total of 55 responses were collected. Just over half the participants (n = 31; 56%) described exercising while receiving immunotherapy, with walking as the most common activity (n = 24; 77%). Participants described a range of physical and emotional benefits of exercise, the most predominant being fatigue reduction. Barriers to exercise also included fatigue and competing physical demands at home or work. Patient understanding of what constitutes exercise appeared to differ from clinical classifications. Conclusions: Results from this study indicate that patients are engaging in exercise while receiving immunotherapy, with the intent of mediating treatment-related fatigue. Identification of preferred exercise activities and barriers will assist in developing tailored exercise interventions for this cohort.


  • Trialling a patient-led cancer care website in an acute cancer care setting

    by Donna Milne, Lisa Sheeran, Matthew Holmes, Gil Tidhar, Sanchia Aranda

    Health ICT is rapidly gaining popularity among policy makers and health consumers. Specific platforms for use in cancer care are missing. Aim: The aim of this pilot study was to: 1) test the feasibility, functionality and usability of a patient-led cancer care web platform: CanCare, in a sample of people undergoing cancer treatment and 2) ascertain if CanCare could enhance communication between patients, family, friends and health professionals. Methods: Cancer patients receiving chemotherapy were invited to participate. Data were collected via semi-structured interviews, online surveys and a website usage program. Results: Nine patients with four different types of cancer completed the study. All saw the potential of the website but many found it too complex to use, particularly when unwell post treatment. Many were frustrated by the lack of integration with existing hospital systems and the need to enter relevant data manually. The cancer-specific information tab rated highly and was used extensively. The website used alone did not promote interactions between family and/or health professionals. Conclusion: A patient-led cancer care website has the potential to help patients manage their cancer care but needs to be intuitive to use, integrated into hospital systems and requires significant family/carer and health professional engagement.


  • Development and validation of a measurement tool to assess perceptions of palliative care

    by Donna Milne, Sanchia Aranda, Michael Jefford, Penelope Schofield

    Objectives: Understanding patient's perceptions about palliative care is necessary to make an effective referral. The aim was to develop and validate a measure of patient perceptions.Methods: Items were generated through patient, family caregiver and health professional interviews. The Perceptions of Palliative Care Instrument (PPCI) was administered to 85 patients with advanced cancer (AC). A subset (n = 39) completed it 7 days later. Participants also completed the Palliative Care Outcome Scale (POS), the Edmonton Symptom Assessment Scale (ESAS) and the Distress Thermometer (DT) for validation purposes.Results: Factor analysis revealed four domains (positive and negative emotional and cognitive reactions to palliative care, emotional and practical palliative care needs and perceptions of health) and eight subscales with factor loadings for all items above 0.51, explaining 61–81% of the total variance. Reliability analyses revealed high internal consistency (Cronbach's alpha coefficients >0.76). Intraclass correlation coefficients showed moderate to strong correlations between time points indicating stability over time. All POS items correlated with two or more dimensions of the PPCI (allr > 0.30); ESAS total distress correlated positively with the palliative care needs domain and the DT with needs and perceived burden (allr > 0.30).Conclusions: The PPCI is a four‐factor, 37‐item measure that assesses perceptions of palliative care held by patients with AC. The measure has good internal consistency, test–retest reliability and convergent validity. Copyright © 2012 John Wiley & Sons, Ltd.


  • Open Access

    Care requirements of patients with advanced cancer within a specialist centre – moving to person-centered approaches

    by Donna Milne, Lisa Sheeran, Tracey Dryden, Linda Mileshkin, Sanchia Aranda

    Despite the prolonged survival of many patients with advanced cancer and the increasing conceptualization of cancer as a chronic illness, care delivery systems within the Australian context continue to manage advanced cancer as an acute illness. Patients living with advanced cancer are managed alongside those with curable cancers in ambulatory models of care that centre on diagnosis, treatment decision-making or post treatment surveillance. Conversely, the needs of people with advanced disease are often complex, requiring high levels of collaboration between providers across acute, palliative and primary care settings in order to move forwards to a more person-centered approach to care. Aims: This paper addresses three specific aims: 1. to identify the care requirements and concerns of patients and their carers; 2. to examine the role of out-reach telephone calls as a component of care; 3. to identify the nurse’s role in care coordination for patients with advanced cancer. Method: Two nurse clinician researchers (CR) managed a cohort of patients with advanced breast (n=12) and gastrointestinal cancers (n=16) over six and nine months respectively. Data were recorded on every interaction between the CRs and the patients, carers and other health professionals. The CRs were interviewed by an independent nurse researcher. Results: The symptoms and issues causing concern to patients and/or carers included pain, weakness, gastrointestinal symptoms, managing appointments and dealing with anxiety. The CR played a major role in coordinating care to address these concerns and found out-reach telephone calls facilitated the process. Conclusions: Patients with advanced cancer have complex needs and care coordination requirements not routinely met in an acute care setting. Input from a nurse working at an advanced level and the use of out-reach telephone calls can assist in meeting these care needs.


  • Promoting evidence‐based care through a clinical research fellowship programme

    by Donna J Milne, Meinir Krishnasamy, Linda Johnston, Sanchia Aranda

    Aim.  This paper reports on the development and evaluation of a multidisciplinary critical appraisal and research utilization‐training programme at one organization with the aim of demonstrating a potential approach to the challenge of ensuring practice is evidence based.Background.  Considerable time and attention is devoted to developing and evaluating new clinical innovations. Nevertheless, it is estimated that a quarter of patients continue to receive treatments that are unnecessary or potentially harmful.Design.  A cross‐sectional qualitative evaluation survey of nurses and allied health staff participating in the training programme.Methods.  After running the programme twice at this organization we sought to evaluate the impact of the programme. Participants were asked to write answers to open‐ended questions to examine personal and professional outcomes of participation.Results.  All respondents found the programme to be worthwhile and beneficial to their everyday practice. Importantly, participants reported feeling more confident when discussing clinical issues within the multidisciplinary team. The majority have presented their work via oral presentations or in publications and many have gone on to enrol in higher degrees.Conclusions.  A critical appraisal and research utilization programme, as described here, has benefits for clinicians in terms of building confidence, knowledge and skill acquisition and also for the organization in terms of provision of evidence‐based care and quality and safety. It successfully addresses commonly reported barriers to research utilization.Relevance to clinical practice.  A programme such as the Clinical Research Fellowship increases clinicians’ ability and confidence to generate research questions that are meaningful to practice and then investigate the issue in a rigorous and timely manner.


  • Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare?

    by D.J. Milne, L.L. Mulder, H.C.M. Beelen, P. Schofield, G.I.J.M. Kempen, S. Aranda

    This study describes the concordance between advanced cancer patients’ self‐report of quality of life and their caregivers’ perception of the patients’ quality of life at two time points. It is often necessary for health professionals to rely on information about the patients’ quality of life that is provided by family caregivers (proxy), even though information from the patients is considered ‘the gold standard’. Therefore, it is important to establish how reliable this proxy information is. Data were collected 4–6 weeks following diagnosis of recurrent or progressive disease, and again 12 weeks later. Fifty‐one patients and their caregivers completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ‐C30), version 2.0 at both time points. Descriptive statistics were used to calculate patient and caregiver scores and describe the sample. The level of agreement between the two scores, the patients’ self‐report and the family caregivers’ score, was calculated on the mean scores of each scale. In general, most caregivers were able to accurately rate the global quality of life, the level of functioning and the degree of symptom distress experienced by the person they were caring for, when compared with the patients’ self‐rating. Caregiver ratings for physical domains tended to be more in agreement with those of patients as compared with ratings of the psychosocial domains. This study suggests information from proxy raters is reliable when the proxy is a family caregiver, and this remains true over time.